Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 69 points (-0.4%) at 16,384 as of Monday, March 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 999 issues advancing vs. 1,928 declining with 160 unchanged. The Drugs industry currently sits down 0.1% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Incyte ( INCY), down 2.5%, Novo Nordisk A/S ( NVO), down 1.4%, Vertex Pharmaceuticals ( VRTX), down 1.4%, Valeant Pharmaceuticals International ( VRX), down 1.0% and Shire ( SHPG), down 0.9%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Illumina ( ILMN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Illumina is down $2.99 (-1.8%) to $165.36 on average volume. Thus far, 1.4 million shares of Illumina exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $163.09-$168.54 after having opened the day at $167.68 as compared to the previous trading day's close of $168.35. Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $22.0 billion and is part of the health care sector. Shares are up 55.0% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold. TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Illumina Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.